Peroxisome Proliferator-Activated Receptor-γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition

Epithelial-mesenchymal transition (EMT) was shown to confer tumor cells with abilities essential for metastasis, including migratory phenotype, invasiveness, resistance to apoptosis, evading immune surveillance, and tumor stem cell traits. Therefore, inhibition of EMT can be an important therapeutic strategy to inhibit tumor metastasis. Here, we show that activation of peroxisome proliferator-activated receptor γ (PPAR-γ) inhibits transforming growth factor β (TGF-β)-induced EMT in lung cancer cells and prevents metastasis by antagonizing Smad3 function. Activation of PPAR-γ by synthetic ligands (troglitazone and rosiglitazone) or by a constitutively active form of PPAR-γ prevents TGF-β–induced loss of E-cadherin expression and inhibits the induction of mesenchymal markers (vimentin, N-cadherin, fibronectin) and matrix metalloproteases. Consistently, activation of PPAR-γ also inhibited EMT-induced migration and invasion of lung cancer cells. Furthermore, effects of PPAR-γ ligands were attenuated by siRNA-mediated knockdown of PPAR-γ, indicating that the ligand-induced responses are PPAR-γ dependent. Selective knockdown of Smad2 and Smad3 by siRNA showed that TGF-β–induced EMT is Smad3 dependent in lung cancer cells. Activation of PPAR-γ inhibits TGF-β–induced Smad transcriptional activity but had no effect on the phosphorylation or nuclear translocation of Smads. Consistently, PPAR-γ activation prevented TGF-β–induced transcriptional repression of E-cadherin promoter and inhibited transcriptional activation of N-cadherin promoter. Finally, treatment of mice with troglitazone or knockdown of Smad3 in tumor cells significantly inhibited TGF-β–induced experimental metastasis in SCID-Beige mice. Together, with the low toxicity profile of PPAR-γ ligands, our data show that these ligands may serve as potential therapeutic agents to inhibit metastasis. Mol Cancer Ther; 9(12); 3221–32. ©2010 AACR.

[1]  J. Bourke,et al.  Effects of PPARγ ligands on TGF-β1-induced epithelial-mesenchymal transition in alveolar epithelial cells , 2010, Respiratory research.

[2]  Y. Barak,et al.  Peroxisome proliferator‐activated receptor‐γ abrogates Smad‐dependent collagen stimulation by targeting the p300 transcriptional coactivator , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Jessica M. Silvaggi,et al.  Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin , 2008, Clinical Cancer Research.

[4]  E. Bottinger,et al.  Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. , 2008, The Journal of clinical investigation.

[5]  V. Keshamouni,et al.  Chemotherapeutic Drugs Induce PPAR-γ Expression and Show Sequence-Specific Synergy with PPAR-γ Ligands in Inhibition of Non–Small Cell Lung Cancer , 2008 .

[6]  M. Shimizu,et al.  Synergistic Effects of PPARγ Ligands and Retinoids in Cancer Treatment , 2008, PPAR research.

[7]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[8]  E. Lander,et al.  Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. , 2008, Cancer research.

[9]  R. Nemenoff.  Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors. , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  H. Kajiyama,et al.  Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. , 2007, International journal of oncology.

[11]  E. Siegel,et al.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Suster,et al.  Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers , 2007, Clinical Cancer Research.

[13]  A. Teramoto,et al.  Elevated Cell Invasion Is Induced by Hypoxia in a Human Pituitary Adenoma Cell Line , 2007, Cell adhesion & migration.

[14]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[15]  Gilbert S Omenn,et al.  Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. , 2006, Journal of proteome research.

[16]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[17]  J. Roman,et al.  Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways , 2006, Molecular Cancer Therapeutics.

[18]  R. Kucherlapati,et al.  Deletion of Smad2 in Mouse Liver Reveals Novel Functions in Hepatocyte Growth and Differentiation , 2006, Molecular and Cellular Biology.

[19]  E. Brown,et al.  Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.

[20]  S. Prime,et al.  Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF‐β1 involves MAPK, Smad and AP‐1 signalling pathways , 2005, Journal of cellular biochemistry.

[21]  D. Tarin,et al.  The fallacy of epithelial mesenchymal transition in neoplasia. , 2005, Cancer research.

[22]  C. Heldin,et al.  TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. , 2005, Molecular biology of the cell.

[23]  Gerard C Blobe,et al.  Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Q. Xie,et al.  RETRACTED: TGF-β1 induces alveolar epithelial to mesenchymal transition in vitro , 2004 .

[25]  J. Shelhamer,et al.  Transforming Growth Factor-β (TGF-β) Activates Cytosolic Phospholipase A2α (cPLA2α)-mediated Prostaglandin E2 (PGE)2/EP1 and Peroxisome Proliferator-activated Receptor-γ (PPAR-γ)/Smad Signaling Pathways in Human Liver Cancer Cells , 2004, Journal of Biological Chemistry.

[26]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .

[27]  V. Keshamouni,et al.  Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer , 2004, Oncogene.

[28]  Jean Paul Thiery,et al.  Epithelial-mesenchymal transitions in development and pathologies. , 2003, Current opinion in cell biology.

[29]  B. Spiegelman,et al.  Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study , 2003, Breast Cancer Research and Treatment.

[30]  C. Arteaga,et al.  Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases , 2002 .

[31]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[32]  M. Lazar,et al.  Differential Gene Regulation by PPARγ Agonist and Constitutively Active PPARγ2 , 2002 .

[33]  M. Lazar,et al.  Differential Gene Regulation by PPAR Agonist and Constitutively Active PPAR 2 , 2002 .

[34]  T. Willson,et al.  Peroxisome Proliferator-activated Receptor γ Inhibits Transforming Growth Factor β-induced Connective Tissue Growth Factor Expression in Human Aortic Smooth Muscle Cells by Interfering with Smad3* , 2001, The Journal of Biological Chemistry.

[35]  J. Auwerx,et al.  Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. , 2001, Journal of molecular endocrinology.

[36]  R. Clough,et al.  Plasma transforming growth factor‐β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma , 1999, Cancer.

[37]  B. Spiegelman,et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[39]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[40]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[42]  V. Keshamouni,et al.  Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. , 2008, Neoplasia.

[43]  J. Roman,et al.  Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. , 2006, Molecular cancer therapeutics.

[44]  J. Zavadil,et al.  TGF-beta and epithelial-to-mesenchymal transitions. , 2005, Oncogene.

[45]  Q. Xie,et al.  TGF-beta1 induces alveolar epithelial to mesenchymal transition in vitro. , 2004, Life sciences.

[46]  V. Keshamouni,et al.  Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. , 2004, Oncogene.

[47]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.

[48]  C. Arteaga,et al.  Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. , 2002, The Journal of clinical investigation.

[49]  M. Lazar,et al.  Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2. , 2002, Molecular endocrinology.

[50]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[51]  Y. Shim,et al.  Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. , 1999, Anticancer research.

[52]  Keunchil Park,et al.  Reduced transforming growth factor-β type II receptor (TGF-β RII) expression in adenocarcinoma of the lung , 1999 .

[53]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.